glp 1 rhabdomyolysis A Closer Look at the Dermatological Profile of GLP-1 Agonists glp 1 rhabdomyolysis Mechanisms of

An FDA-approved formulation under medical supervision differs from a compounded protocol obtained through a brief telehealth questionnaire

N Engl J Med 345(12):851860 Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H et al (2001Effects) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Exenatide is eliminated primarily through the kidneys, and its use is not recommended in patients with a creatinine clearance (CrCl) of 30 mL/min

Sustainable outcomes still depend on supporting the whole person

In published data, irregular menstrual cycles decreased from 85.7% to 32.1% among women taking tirzepatide

Is there a risk for semaglutide misuse?: focus on the Food and Drug Administrations FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset